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Abstract
Randomized trials suggest that statin treatment may lower blood pressure and
influence cardiovascular autonomic function (CVAF), but the impact of dura-
tion of usage, discontinuation, and adherence to this therapy is unknown. We
examined these issues with regard to blood pressure (BP)-related variables in a
large, population-based study. Participants were 4942 adults (58% male; aged
50–84 years): 2179 on statin treatment and 2763 untreated. Days of utilization,
adherence (proportion of days covered ≥0.8), and discontinuation (non-use for
≥30 days immediately prior to BP measurement) of three statins (atorvastatin,
pravastatin, and simvastatin) over a period of up to 2 years was monitored ret-
rospectively from electronic databases. Systolic BP (SBP), diastolic BP (DBP),
augmentation index, excess pressure, reservoir pressure, and CVAF (pulse rate
and BP variability) parameters were calculated from aortic pressure waveforms
derived from suprasystolic brachial measurement. Days of statin treatment had
inverse relationships with pulse rate variability parameters in cardiac arrhythmic
participants (20–25% lower than in statin non-users) and with most arterial
function parameters in everyone. For example, compared to untreated partici-
pants, those treated for ≥659 days had 3.0 mmHg lower aortic SBP (P < 0.01).
Discontinuation was associated with higher brachial DBP and aortic DBP (for
both, b = 2.0 mmHg, P = 0.008). Compared to non-adherent statin users,
adherent users had lower levels of brachial SBP, brachial DBP, aortic DBP, aor-
tic SBP, and peak reservoir pressure (b = 1.4 to 2.6 mmHg). In conclusion,
in a real-world setting, statin-therapy duration, non-discontinuation and adher-
ence associate inversely with BP variables and, in cardiac arrhythmias, CVAF
parameters.
Abbreviations
AIx, augmentation index; BMI, body mass index; BP, blood pressure; CVAF, car-
diovascular autonomic function; CV, cardiovascular; DBP, diastolic BP; HRV, heart
rate variability; PDC, proportion of days covered, PPV, pulse pressure variation;
RMSSD, root mean square of successive differences; SBP, systolic BP, SD, standard
deviation; ViDA, Vitamin D Assessment.
Introduction
Statins are widely prescribed for their lipid-lowering
effects and a recent systematic review found that they
may also have small blood pressure (BP)-lowering prop-
erties (Briasoulis et al. 2013). In addition, some clinical
trials have found that statins may affect measures of car-
diovascular autonomic function such as heart rate
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variability (HRV) (Millar and Floras 2014). However, the
clinical importance of these effects is not clear (Millar
and Floras 2014) and merits further investigation. More-
over, the efficacy of statins in real-world settings may be
inferior to that seen in trials (Andrade et al. 1995).
Past observational studies have found that adherence to
statin therapy correlates negatively with cardiovascular
burden, while discontinuation correlates positively (De
Vera et al. 2014). This could potentially be attributed, in
part, to the effects of statins on BP. But as far as we
know, this has not been previously explored. Such an
assessment could help understand whether the impact of
statin adherence and discontinuation on cardiovascular
events is mediated through effects on arterial and cardio-
vascular autonomic function. Another use of this analysis
is that it may provide better recognition of the pharma-
cology of statins (Reidenberg 2011).
Further, in prior studies evaluating the antihypertensive
properties of statins, these effects almost exclusively have
been measured by brachial BP. In comparison, few studies
have investigated their impact on parameters measured
from the aortic pressure waveform such as augmentation
index (Manisty et al. 2009; Kanaki et al. 2013; Ballard
et al. 2014). This could be important as these variables
predict cardiovascular events independently of brachial
BP (Vlachopoulos et al. 2010a,b).
The objectives of this study were to examine relation-
ships that patterns of statin use – including discontinua-
tion and adherence – have with brachial BP, measures of
arterial function (derived from the aortic pressure wave-
form), and cardiovascular autonomic function (assessed
by HRV and other parameters). This was explored in a
population-based study; a real-world setting that may
provide different results but complimentary information
to that obtained from clinical trials. As the mechanisms
for these associations may involve serum cholesterol (Bri-
asoulis et al. 2013; Millar and Floras 2014), we also
sought to examine the contributions of this parameter to
the relationships, which may give additional insight into
this issue.
Materials and Methods
Participants
This study is an analysis of data collected at baseline and
retrospectively (before baseline) in the ViDA (Vitamin D
Assessment) study, a randomized controlled trial of the
effect of vitamin D supplementation on health-related
outcomes. Inclusion criteria were men and women aged
50–84 years and resident in Auckland at recruitment.
Exclusion criteria included: (1) diagnosis of a terminal ill-
ness and/or in hospice care, (2) intending to leave New
Zealand during the follow-up period, (3) taking vitamin
D supplements (including cod liver oil) of >600 IU per
day, (4) history of renal stones, hypercalcemia, or medical
conditions that can cause hypercalcemia, and (5) baseline
serum calcium >2.50 mmol/L. All baseline data were col-
lected between 2011 and 2012. Ethics approval was pro-
vided by the Ministry of Health Multi-region Ethics
committee (MEC/09/08/082). Written, informed consent
was obtained from each participant. Full details have been
published elsewhere (Scragg et al. 2015)
Questionnaire, anthropometric and
cholesterol variables
All measurements (both in this section and the next two)
were carried out by trained staff using a standardized pro-
tocol. Questionnaires administered by interviewers were
used to collect data on age, sex, ethnicity (defined by self-
identification), smoking, diabetes, and history of cardio-
vascular disease. Without shoes and in light clothing,
height was measured with a stadiometer to the nearest
0.1 cm, and weight with digital scales to the nearest 0.1 kg.
Body mass index (BMI) was calculated as body weight
(kg)/height (m)2. A blood sample was taken, and collected
aliquots were stored at 80°C (112°F) and later mea-
sured for serum total cholesterol on a Siemens Advia 2400
analyser (Siemens Healthcare Diagnostics, Germany).
Arterial function measures
Sitting brachial BP was measured three times after
15 min rest with an Omron T9P oscillometric device
(Omron Healthcare, Kyoto, Japan); the mean of the two
closest measurements were used for analyses. Participants
were considered to be hypertensive if they had a brachial
SBP of ≥140 mmHg, a brachial diastolic BP (DBP) of
≥90 mmHg, and/or were receiving antihypertensive
medications.
Suprasystolic oscillometry was carried out using a BP+
device (Uscom, Sydney, Australia) (formerly called a R6.5
cardiovascular monitor; Pulsecor, Auckland, New Zeal-
and), with an appropriately sized cuff positioned over the
left upper arm. The BP+ device has been shown to: (1)
yield central systolic blood pressures that are highly corre-
lated with those assessed by catheter measurement at the
ascending aorta or aortic arch (Lin et al. 2012) and, (2)
measure central systolic BP with good intratest and intert-
est reliability (Climie et al. 2012). To improve the quality
of the waveforms used in analyses, we decided a priori to
exclude readings with a signal-to-noise ratio of <6 dB.
Augmentation index (AIx), an index of arterial stiff-
ness and wave reflection (Davies et al. 2010), was
calculated from the aortic pressure waveform using
2016 | Vol. 4 | Iss. 6 | e00276
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custom-written Matlab software (Mathworks, Natick,
MA). A meta-analysis has shown AIx to be a predictor
of CV events (Vlachopoulos et al. 2010a).
Aortic pressure was separated into reservoir and wave
components using custom-written Matlab software. Reser-
voir pressure was calculated from aortic pressure mea-
surements only (Davies et al. 2014), while excess pressure
was calculated as measured aortic pressure minus reser-
voir pressure (Davies et al. 2007). The integrals of the
reservoir and excess pressure waveforms (area under these
waveforms) over the cardiac cycle was used to calculate
reservoir pressure integral and excess pressure integral,
respectively. The latter measures pressure associated with
excess ventricular work and has been shown to predict
CV events independently of brachial SBP (Davies et al.
2014). In addition, peak reservoir and excess pressures
were calculated as the maximum values of the reservoir
and excess pressure waveforms, respectively (Hametner
et al. 2014). The amplitude of the reservoir pressure
waveform has been found to associate positively with the
risk of cardiovascular events independently of brachial BP
(Hametner et al. 2014).
Cardiovascular autonomic function
measures
HRV was assessed from the variability of the beat dura-
tion of the aortic pressure waveforms derived from the
BP+ device. The waveforms spanned approximately
10 seconds; thus analysis was performed on approxi-
mately 10–12 pulse intervals, a period adequate for valid
measurement of HRV (Thong et al. 2003; Schroeder et al.
2004; Nussinovitch et al. 2011, 2012; Munoz et al. 2015).
Two time-domain measures were used: standard deviation
(SD) of pulse intervals (in ms; analogous to SD of NN
intervals of an electrocardiographic record) and root
mean square of successive differences (RMSSD) (Malik
et al. 1996; Hilz and D€utsch 2006). RMSSD (in msec)
was calculated as the square root of the mean of the
squared differences in the duration of successive pulse
intervals and reflects parasympathetic activity (Malik et al.
1996; Hilz and D€utsch 2006).
Baroreflex sensitivity was assessed using the sequence
method, which establishes the slope of the relationship
between changes in pulse interval and SBP across succes-
sive cardiac cycles (Parlow et al. 1995; Persson et al.
2001). Pulse intervals were paired with the SBP (systolic
pressure wave amplitude) of the preceding cardiac cycle
(that is, a one-beat delay), as illustrated elsewhere (Parlow
et al. 1995; Persson et al. 2001). Instances in which SBP
and pulse intervals (PI) both increased (+PI/+SBP) or
decreased (PI/SBP) from one beat to the next were
detected. Due to the limited number of beats, we did not
enforce the practice (Parlow et al. 1995) that these changes
had to occur over at least three consecutive beats. The
minimum SBP change between pulse intervals that was
accepted was 1 mmHg (Kardos et al. 2001). Baroreflex
sensitivity (in msec/mmHg) was calculated as the mean of
all +PI/+SBP and PI/SBP slopes (Kardos et al. 2001).
Aortic pulse pressure variation (PPV) was calculated as
(maximum pulse pressure – minimum pulse pressure)/
mean pulse pressure from individual beats of the aortic
pressure waveform (Lansdorp et al. 2011). Although BP
variability is influenced by the mechanical effects of respi-
ration on intrathoracic pressure (Zhang et al. 2002), it
may also reflect sympathetic activity (Zhang et al. 2002;
Brychta et al. 2007).
Because of the potential influence of cardiac arrhyth-
mias on HRV, analysis of relationships for cardiovascular
autonomic function were performed among participants
identified as not having a cardiac arrhythmia and results
for all others (cardiac arrhythmia identified as being pre-
sent) were shown separately. While HRV assessment is
conventionally applied to people without a cardiac
arrhythmia, it can also be carried out to provide informa-
tive data in people with one (Van Den Berg et al. 1997).
Cardiac arrhythmia was defined as having a history of this
condition or if they had a measured RMSSD value of
>100 msec, which identifies patients with atrial fibrillation
(determined via ECG tracings) with very high sensitivity
and specificity (Oh et al. 2013).
Medications
Records of all medicine prescriptions administered for
participants before and after their interview dates were
collected from the Ministry of Health databases, which
includes all dispensed prescriptions. Such data included
the medicine name, date dispensed, dose, daily dose, fre-
quency, and days of supply. For the calculations of statin
days of supply (which was used to indicate duration of
use), discontinuation and adherence, we focused only on
prescriptions dispensed prior to (not after) the interview
dates (when BP measurements were taken) and with at
least 60 days of follow-up.
Discontinuation of statin treatment was defined as con-
tinuous non-use of statins in the 30 days immediately prior
to BP measurement. Adherence to statin medications was
measured by proportion of days covered (PDC), calculated
as the total number of days in which they were supplied
divided by the observation time interval (Choudhry et al.
2009). The latter was the time difference between statin ini-
tiation and the interview date. To account for the utiliza-
tion of more than one statin, the numerator used to
calculate PDC was the number of days in which there was
≥1 statin medication available. Participants with
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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PDC ≥ 80% were classified as adherent, in accordance with
standard practice (Choudhry et al. 2009).
Statistical analysis
Data were analyzed using SAS version 9.3 (SAS Institute,
Cary, NC). Because of their positively skewed distributions,
excess pressure integral, RMSSD, SD of pulse intervals and
baroreflex sensitivity were converted to loge for analyses.
Differences in the mean values between two groups were
compared using analysis of variance and categorical vari-
ables were compared using v2 tests. Associations between
statins and waveform parameters were examined by multi-
ple linear regression. The independent variables for such
analyses comprised statin use, antihypertensive treatment,
sex, age, ethnicity, smoking, diabetes, history of cardiovas-
cular disease, and BMI. Statin daily dose was not included
as an independent variable as it was not significantly related
to the outcome variables. Two-sided P < 0.05 were consid-
ered statistically significant. No P-value correction was
applied to account for multiple hypothesis tests, as sug-
gested by Rothman (Rothman 1990).
Results
Characteristics of participants stratified by statin treatment
are shown in Table 1. Analysis was performed on 4942
adults, 44% of whom received statin therapy. Treated par-
ticipants received, almost exclusively, atorvastatin and/or
simvastatin. Most received simvastatin only (n = 1206),
fewer took atorvastatin only (n = 549) and some received
both (n = 422). Only four participants were prescribed
pravastatin. For all three statins, the mean daily dose over
the follow-up period was about 30 mg. The sample
comprised individuals who were either currently receiving
antihypertensive therapy or were not. Similarly, the hyper-
tensive status of the participants was mixed, with most
being hypertensive. Across the two treatment groups, age,
sex, ethnicity, hypertension status, antihypertensive treat-
ment, smoking, diabetes, history of cardiovascular disease,
and BMI differed. So too did cholesterol, with statin users
having lower levels. The time period between statin initia-
tion and follow-up averaged 1.6 years (mean; median was
1.8 years) and was as high as 2.0 years.
Associations with duration of statin use
Table 2 shows relationships of duration of statin use
(stratified into approximate quartiles) with measures of
arterial and cardiovascular autonomic function. Longer
duration of statin treatment (periods of 621 days and
above) was associated with lower brachial SBP, brachial
DBP, aortic SBP, aortic DBP, and peak reservoir pressure.
These effect sizes were not large; for example, the differ-
ences did not exceed more than 4 mmHg for these
parameters. Of the cardiovascular autonomic function
parameters, both loge(RMSSD) and loge(SD of pulse
intervals) were inversely related to duration of statin use
(lower with ≥447 days of treatment) among those identi-
fied as arrhythmic. The beta-coefficients for these two
parameters for ≥447 days of treatment ranged from
0.225 to 0.282, indicating percentage differences of
between 20% (100 9 (1 – e0.225)) and 25% (100 9
(1–e0.282)) for RMSSD and SD of pulse intervals.
Table 1. Characteristics of participants stratified by statin treatment.
Variable
Statin treatment
P-valueUntreated Treated
n 2763 2179
Age (years), mean  SD 64.9  8.3 68.1  8.0 <0.001
Male (%) 52 65 <0.001
Ethnicity (%)
European/Other 85 81 <0.001
Maori 5 6
Pacific 5 8
South Asian 4 6
Hypertension (%) 56 82 <0.001
Antihypertensive
treatment (%)
23 59 <0.001
Smoking (%)
Non-smoker 54 49 <0.001
Ex-smoker 40 45
Current smoker 6 6
Diabetes mellitus (%) 3 19 <0.001
History of
cardiovascular disease (%)
4 25 <0.001
Body mass index (kg/m2),
mean  SD
27.6  4.9 29.4  5.0 <0.001
Cholesterol, mean  SD
Total (mmol/L) 5.3  1.0 4.3  1.0 <0.001
Non-HDL (mmol/L) 3.8  0.9 3.0  0.9 <0.001
Statin treatment (%)
Atorvastatin 25
Simvastatin 55
Atorvastatin + simvastatin 19
Pravastatin 0.2
Mean daily dose of statins over follow-up (mg)*
Atorvastatin 27
Simvastatin 29
Pravastatin 32
Time from statin initiation to follow-up† (days),
Median  interquartile
range
645  80
Range (60–719)
SD, standard deviation.
*Calculated as cumulative dose dispensed (mg)/cumulative days of
supply.
†Follow-up date is baseline interview date, when blood pressure-
related variables were measured.
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Influence of discontinuation
Discontinuation was then added to the models for the
abovementioned results on statin duration (illustrated in
Table 2) in order to evaluate the impact of this on the BP-
related variables. In addition, this analysis was restricted to
treated participants only to enable direct comparisons
between discontinuers and non-discontinuers who received
statin therapy. Altogether, the covariates for these analyses
were days of supply, as well as demographics, antihyperten-
sive use, smoking, diabetes, history of cardiovascular disease,
and BMI. These results are provided in Table 3. This table
shows that, for the same duration of use, statin discontinua-
tion ≥30 days immediately prior to BP measurement was
unrelated to most arterial function parameters and all car-
diovascular autonomic function variables. But it was associ-
ated with slightly higher levels (by 2 mmHg) of brachial
DBP and aortic DBP.
Relationships with adherence
To investigate the impact of adherence to statin medica-
tion on waveform parameters, models for Table 3 were
reanalyzed with PDC groups (indicative of adherence) as
independent variables instead of discontinuation and days
of supply (Table 4). Among participants who received
statin prophylaxis, people who were adherent to such
treatment (PDC ≥ 0.8) had slightly lower BP and peak
reservoir pressure than those who were non-adherent
(PDC < 0.8). For brachial DBP and aortic DBP, this was
particularly the case among people who were most adher-
ent (PDC = 1). Out of the cardiovascular autonomic
function variables, aortic PPV was lower in the adherent
group among arrhythmic participants but all other mea-
sures were unrelated to adherence.
Impact of cholesterol
As expected, total cholesterol had inverse, dose-dependent
relationships with duration of statin use (Table S1). The
analyses for Table 2 were repeated, adjusting for total
cholesterol (Table S1). Comparison of both tables shows
that statistical adjustment for cholesterol notably attenu-
ated relationships of arterial function parameters and
eliminated all of these except for DBP variables
(Table S1). In contrast, relationships of cardiovascular
Table 3. Arterial and cardiovascular autonomic function in relation to statin discontinuation, adjusted for days of supply#.
Variable
Mean (SE) of
non-discontinuers
(reference)
Mean difference
(95% CI) for
discontinuers P-value
Arterial
function
measure
n 1901 278
Brachial SBP (mmHg) 138.7 (0.9) 1.3 (1.3, 4.0) 0.33
Brachial DBP (mmHg) 75.1 (0.5) 2.0 (0.5, 3.5) 0.008
Aortic SBP (mmHg) 130.3 (0.9) 1.5 (1.1, 4.1) 0.27
Aortic DBP (mmHg) 76.2 (0.5) 2.0 (0.5, 3.5) 0.008
Augmentation index 29.1 (0.5) 0.2 (1.3, 1.8) 0.76
Reservoir pressure integral (mmHg.sec) 88.0 (0.9) 0.7 (1.8, 3.3) 0.57
loge(EPI (mmHg. sec)) (910
2) 110.3 (2.2) 4.0 (10.4, 2.4) 0.22
Peak reservoir pressure (mmHg) 120.2 (0.8) 2.0 (0.4, 4.4) 0.10
Peak excess pressure (mmHg) 18.0 (0.4) 0.6 (1.7, 0.5) 0.26
CV autonomic
function
measure
No cardiac arrhythmia
n 1325 198
loge(RMSSD (msec)) (910
2) 340.9 (4.1) 3.5 (15.0, 8.0) 0.55
loge(SD of pulse intervals (msec)) (910
2) 247.3 (4.6) 6.4 (19.6, 6.7) 0.34
loge(BRS (msec/mmHg)) (910
2) 131.6 (5.3) 0.3 (15.3, 14.7) 0.97
Aortic pulse pressure variation (9102) 35.4 (0.9) 1.2 (1.5, 3.8) 0.38
Cardiac arrhythmia present
n 576 80
loge(RMSSD (msec)) (910
2) 485.9 (11.8) 7.2 (27.2, 41.5) 0.68
loge(SD of pulse intervals (msec)) (910
2) 372.9 (11.1) 6.1 (26.3, 38.6) 0.71
loge(BRS (msec/mmHg)) (910
2) 161.3 (11.1) 13.5 (18.7, 45.7) 0.41
Aortic pulse pressure variation (9102) 42.3 (1.9) 3.1 (2.4, 8.7) 0.27
SE, standard error; CI, confidence intervals; EPI, excess pressure integral; CV, cardiovascular; RMSSD, root mean square of successive differences;
SD, standard deviation.
#Adjusted for duration of use, age, sex, ethnicity, antihypertensive medication use, smoking, diabetes, history of cardiovascular disease and BMI.
P-values test for differences across the 2 groups. 95% confidence intervals that do not encompass zero and significant main effects (P < 0.05) are
in bold.
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autonomic functions in arrhythmic participants were not
reduced by adjustment for cholesterol.
Associations in hypertensive participants
The analyses for Table 2 were repeated for hypertensive
participants only and these results are displayed in
Table S2. The beta-coefficients for the hypertensive sam-
ple (Table S2) were larger than for the corresponding
analyses in the total sample (Table 2). Fewer than
621 days of treatment was inversely related to arterial
function measures (SBP, DBP, and peak reservoir pres-
sure variables) in the hypertensive sample (Table S2),
unlike in the total sample (Table 2).
Discussion
In a large, population-based study, we found that long
periods of statin utilization were associated with lower
levels of most arterial function parameters (SBP, DBP,
and peak reservoir pressure variables). Admittedly, the
sizes of these effects were not substantial. For example,
the largest difference observed with aortic DBP was
2.6 mmHg, which represents 3% of the average value
among untreated participants (Table 2). For the same
duration of use, DBP variables were higher among those
who discontinued use for at least 30 days immediately
prior to BP measurement. Statin use was associated with
lower levels of some arterial function parameters in peo-
ple who were adherent to such therapy. Finally, duration
of use was inversely related to HRV parameters in people
with diagnosed or suspected cardiac arrhythmias. Specifi-
cally, RMSSD and SD of pulse intervals were 20–25%
lower in statin users with ≥447 days of treatment, indicat-
ing that these differences were of large magnitude.
The modest, inverse relationships between statins and
brachial BP concur with findings of clinical trials (Mangat
et al. 2007). For example, a meta-analysis found that the
effect size with statin use was 2.62 mmHg (95% confi-
dence interval: 3.41 to 1.84 mmHg) for SBP and
0.94 mmHg (95% confidence interval: 1.31 to
0.57 mmHg) for DBP (Briasoulis et al. 2013), which is
line with our results (Table 2). Thus, we extend the trial
findings by showing this to be the case in a real-world
Table 4. Arterial and cardiovascular autonomic function in relation to statin adherence#.
Variable
Mean (SE) of
non-adherent
(reference)
Mean difference (95% CI) for adherent
P-valuePDC < 0.8 PDC = 0.8–0.99 PDC = 1
Arterial function
measures
n 389 605 1185
Brachial SBP (mmHg) 140.5 (1.2) 2.6 (5.0, 0.2) 1.8 (4.0, 0.4) 0.09
Brachial DBP (mmHg) 76.6 (0.7) 1.4 (2.7, 0.1) 1.9 (3.1, 0.7) 0.009
Aortic SBP (mmHg) 132.2 (1.2) 2.6 (4.9, 0.3) 2.0 (4.2, 0.2) 0.08
Aortic DBP (mmHg) 77.7 (0.7) 1.4 (2.7, 0.1) 1.9 (3.1, 0.6) 0.01
Augmentation index 29.4 (0.7) 0.6 (2.0, 0.8) 0.2 (1.5, 1.2) 0.59
Reservoir pressure integral (mmHg.sec) 88.7 (1.2) 1.0 (3.2, 1.3) 0.7 (2.9, 1.4) 0.69
loge(EPI (mmHg.s)) (910
2) 108.6 (2.9) 1.3 (6.9, 4.3) 3.5 (1.8, 8.8) 0.08
Peak reservoir pressure (mmHg) 122.3 (1.1) 2.6 (4.7, 0.5) 2.3 (4.3, 0.3) 0.04
Peak excess pressure (mmHg) 17.7 (0.5) 0.0 (1.0, 0.9) 0.6 (0.3, 1.5) 0.18
CV autonomic
function
measures
No cardiac arrhythmia
n 277 436 810
loge(RMSSD (msec)) (910
2) 337.7 (5.3) 0.9 (9.2, 11.1) 5.7 (3.9, 15.3) 0.36
loge(SD of pulse intervals (msec)) (910
2) 243.9 (6.0) 0.7 (10.9, 12.3) 5.6 (5.4, 16.5) 0.46
loge(BRS (msec/mmHg)) (910
2) 135.3 (6.9) 1.8 (11.4, 15.0) 8.6 (21.1, 3.8) 0.11
Aortic pulse pressure variation (9102) 36.5 (1.2) 1.4 (3.7, 0.9) 1.4 (3.6, 0.8) 0.40
Cardiac arrhythmia present
n 112 169 375
loge(RMSSD (msec)) (910
2) 502.4 (15.7) 20.3 (50.3, 9.7) 21.4 (49.5, 6.7) 0.30
loge(SD of pulse intervals (msec)) (910
2) 387.4 (14.7) 15.8 (44.0, 12.5) 20.1 (46.6, 6.5) 0.33
loge(BRS (msec/mmHg)) (910
2) 176.6 (14.9) 11.5 (40.1, 17.0) 21.5 (48.2, 5.3) 0.27
Aortic pulse pressure variation (9102) 47.3 (2.5) 6.1 (10.9, 1.3) 5.8 (10.4, 1.3) 0.02
SE, standard error; CI, confidence intervals; EPI, excess pressure integral; PDC, proportion of days covered; CV, cardiovascular; RMSSD, root mean
square of successive differences; SD, standard deviation.
#Adjusted for age, sex, ethnicity, antihypertensive medication use, smoking, diabetes, history of cardiovascular disease, and BMI. P -values test for
differences across the three groups.
95% confidence intervals that do not encompass zero and significant main effects (P < 0.05) are in bold.
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setting. Clinical trials have reported negative associations
with AIx (Manisty et al. 2009; Kanaki et al. 2013), but
our relationships for this parameter were not statistically
significant, although they were in the same direction. Our
work further adds to the literature by demonstrating, for
the first time, that statin use is associated with lower
reservoir pressure parameters (peak and area) but not
excess pressure measures (Table 2). The absence of an
effect on the latter suggests that excess pressure variables
may be difficult to modify with statins, but clinical trials
are required to confirm this.
This study provides new insight into the impact of dis-
continuation of statin therapy on BP, which has not been
previously explored. The finding that some BP variables
were higher among those who discontinued use for
≥30 days immediately prior to BP measurement, even
after adjustment for days of supply, suggests that cessa-
tion of therapy may confer a small increase in BP-related
cardiovascular risk. In support of this, studies have
reported that statin discontinuation is associated with an
elevated risk of cardiovascular events (De Vera et al.
2014). In fact, a few studies have reported that this effect
occurs when the treatment stoppage interval is as short as
1 month (De Vera et al. 2011, 2012), which is the lower
limit for the time-period (30 days prior to BP measure-
ment) that we used to define discontinuation. Further, if
statins had long-term influences on BP (a low “off-rate”),
one might expect discontinuation to have no impact
(Lowy et al. 2011). But since it was associated with higher
levels of some waveform parameters, this could mean that
effects are more short-term (<1 month). The relevance
and importance of our findings are increased because
clinical trials of discontinuation are unlikely to be carried
out for ethical reasons and the prevalence of discontinua-
tion is high (reported to be ≥50% in most studies) (De
Vera et al. 2014).
Adherence to statin therapy is important as this influ-
ences cardiovascular morbidity (De Vera et al. 2014), but
it is not known whether this relationship is mediated
through influences on BP. We show that this could con-
tribute since our results demonstrate that adherent use
was associated with lower levels of SBP, DBP, and peak
reservoir pressure variables. However, as these BP-related
differences were not large (Table 4), the predicted risk
attributable to these is unlikely to account for all the
adverse consequences of poor adherence to statins.
Prior work investigating the influence of statins on car-
diovascular autonomic function comprised small (pre-
dominantly n < 50) clinical trials of predominantly short
duration (mostly ≤8 weeks) and their findings have been
inconsistent (Millar and Floras 2014). Our large and
real-life study of a few years of statin prescription data
therefore helps to provide additional insight into their
efficacy in clinical practice. To interpret our findings for
cardiovascular autonomic function parameters, we note
that HRV is raised in our arrhythmic participants
(Tables 2–4) and elevated HRV is associated with an
increased risk of both atrial fibrillation (Wiesel et al.
2004; Oh et al. 2013) and cardiac mortality (De Bruyne
et al. 1999). Thus, in people with arrhythmias, a signifi-
cantly lower HRV – which we observed with statin use
(up to a 25% difference) – could reduce risk of adverse
cardiovascular outcomes. In support of this, statins have
antiarrhythmic effects and decrease the risk of atrial fibril-
lation (Fauchier et al. 2008), and some antiarrhythmic
drugs lower HRV (Malik et al. 1996). This could occur
through modulation of the autonomic nervous system, as
well as through reductions in inflammation and oxidative
stress (Fauchier et al. 2008). Clinical trials that examine
whether statins reduce HRV in patients with cardiac
arrhythmias are required to verify our findings and evalu-
ate their prognostic significance.
The contributions of serum cholesterol to the effects of
statins on arterial and cardiovascular autonomic function
parameters are unclear (Briasoulis et al. 2013; Millar and
Floras 2014) and investigation into this has been recom-
mended (Millar and Floras 2014). We add understanding
to this issue by showing that cholesterol made large con-
tributions to arterial function associations and, indepen-
dently of it, statin duration of use was related (inversely)
to DBP variables. In contrast, the inverse HRV relation-
ships in arrhythmic participants were minimally influ-
enced by cholesterol and independent of it. Consistent
with this, randomized controlled trial data suggest that
statins reduce sympathetic activity independently of
cholesterol (Lewandowski et al. 2014). This implies that
relying on cholesterol to capture the beneficial impact of
statin therapy may capture influences on arterial function
measures well but underestimate the effects on HRV
parameters.
As lipophilic statins reduce efferent sympathetic out-
flow (Millar and Floras 2014), their hypotensive effects
may be greater in people with hypertension. This pattern
is evident in our data when comparing results for the
total sample (Table 2) with those for hypertensives
(Table S2). Therefore, studies that investigate the antihy-
pertensive effects of statins in normotensive people may
underestimate benefits that occur in hypertensives.
Some limitations and strengths of this study deserve
mention. First, although we adjusted for a wide range of
covariates in our analyses, causal inferences in the find-
ings cannot be made as it is possible that statin utilization
is related to other unknown factors that also affect arterial
function. Nevertheless, as discussed above, the results of
this study are consistent with those from clinical trials.
For example, brachial BP was, at most, nearly 4 mmHg
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lower with statin therapy than without it (Table 2), which
concurs with effect sizes reported in clinical trials (Bria-
soulis et al. 2013). Furthermore, the observation that
cholesterol levels varied with statin use in a manner that
would be expected (Tables 1 and S1–S2) indicates that
this effect, at least, is not obscured by unobserved con-
founders. Second, our cardiovascular autonomic function
measures were collected from BP recordings over a period
of typically 10–12 sec and, while several studies show that
time-domain measures (particularly RMSSD) calculated
from 10-sec recordings can be used to reliably estimate
HRV, a longer sampling interval (typically 5-min) is
preferable (Thong et al. 2003; Schroeder et al. 2004;
Nussinovitch et al. 2011, 2012; Munoz et al. 2015). Third,
the pulse rate variability parameters in our study were
limited to time-domain measures and did not include fre-
quency-domain variables, which may capture different
aspects of autonomic function (Hilz and D€utsch 2006).
Fourth, in baroreflex sensitivity measurement with the
sequence technique, the minimum number of consecutive
cardiac cycles for a baroreflex sequence (pairs of unidirec-
tional changes in pulse interval and SBP) is traditionally
three (Parlow et al. 1995), but we set the lower limit to
one in our calculations. While our modified approach is
not ideal, its validity is supported by the finding that, in
statistical models of ours, baroreflex sensitivity was inver-
sely related to age, BMI and smoking, brachial SBP, and
brachial DBP (data not shown); consistent with research
that used the conventional sequence method approach
(minimum of three beats for a sequence) for baroreflex
sensitivity measurement (Kardos et al. 2001). Finally, the
strengths of this study include the large, population-based
sample, the variety of waveform parameters as endpoints,
and the comparatively long follow-up periods (nearly
2 years of statin prescription data) for many people.
In summary, in a real-world setting and independently
of cholesterol, duration of statin use had sizeable, inverse
relationships with HRV parameters in those with diag-
nosed or suspected cardiac arrhythmias. Among everyone,
adherence and longer periods of utilization were associ-
ated with lower, more favorable levels of most arterial
function parameters: brachial and aortic SBP and DBP,
and peak reservoir pressure. Conversely, discontinuation
for at least 1 month immediately prior to baseline was
related to higher levels of brachial and aortic DBP. These
arterial function associations were almost exclusively
cholesterol-dependent, although still independent of
cholesterol in some cases.
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